精密科学 EXAS 深 沪
已收盘 01-30 16:00:00 美东时间
102.34
+0.040
+0.04%
华盛通- 最 高102.555
- 今 开102.32
- 成交量 246.72万股
- 最 低 102.31
- 昨 收 102.30
- 总市值 193.42亿
- 52周最高 102.66
- 市盈率 静 --
- 换手率 1.31%
- 52周最低 38.8118
- 委 比 83.80%
- 总股本 1.89亿
- 历史最高 159.54
- 量 比 1.13
- 振 幅 0.24%
- 历史最低 4.67
- 每 手 1
- 风险率 20.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-German Cartel Office Approved Planned Acquisition Of Exact Sciences By Abbott
BRIEF-German Cartel Office Approved Planned Acquisition Of Exact Sciences By Abbott Jan 30 (Reuters) - Abbott Laboratories ABT.N : GERMAN CARTEL OFFICE: APPROVED PLANNED ACQUISITION OF EXACT SCIENCES CORPORATION BY ABBOTT LABORATORIES IN PRELIMINARY PROCEEDINGS Source text: [ID:] Further company cov
01-30 16:36
Abbott Q4 sales misses analyst expectations, hurt by diagnostics unit's challenges
Abbott Q4 sales misses analyst expectations, hurt by diagnostics unit's challenges Overview Healthcare co's Q4 adjusted EPS grew 12%, meeting analyst expectations Q4 sales increased 4.4% reported, 3.0% organic, excluding COVID-19 test sales, but misses analyst expectations Company announced acquisit
01-22 20:40
美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
This Domino's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
01-20 21:56
Mizuho Downgrades Exact Sciences to Neutral, Raises Price Target to $105
Mizuho analyst Anthony Petrone downgrades Exact Sciences (NASDAQ:EXAS) from Outperform to Neutral and raises the price target from $85 to $105.
01-20 21:49
美股大行评级 | 潜在涨幅36.7%！LMRI获多家大行首予超配评级； 瑞银下调甲骨文目标价从325美元至280美元
今日重点评级关注：HC Wainwright & Co.：维持Assertio Holdings"买入"评级，目标价从3美元升至35美元；HC Wainwright & Co.：维持万达生物制药"买入"评级，目标价从20美元升至22美元
01-06 17:52
Evercore ISI Group Downgrades Exact Sciences to In-Line, Maintains Price Target to $105
Evercore ISI Group analyst Vijay Kumar downgrades Exact Sciences (NASDAQ:EXAS) from Outperform to In-Line and maintains the price target from $105 to $105.
01-06 01:58
Top 2 Health Care Stocks That May Crash In Q1
As of Jan. 2, 2026, two stocks in the health care sector could be flashing a re...
01-02 21:58
Smart Oncology: 5 Stocks Chasing the $317B Prize
Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC, Dec. 31, 2025 /PRNewswire/ -- The precision oncology market surged to $139.4 billion in 2025 and i...
2025-12-31 20:25
Exact Sciences Approves Executive Bonus Acceleration Amid Abbott Merger
The latest announcement is out from Exact Sciences ( ($EXAS) ). On November 19,...
2025-12-29 21:59
